Ποια είναι η τιμή για GeneOne Life Science, Inc. (011000)

Η τιμή για GeneOne Life Science, Inc. (011000) είναι $1.85

Ποια είναι η κεφαλαιοποίηση αγοράς για GeneOne Life Science, Inc. (011000)

Η κεφαλαιοποίηση αγοράς για GeneOne Life Science, Inc. (011000) είναι $32.07M

GeneOne Life Science, Inc. (011000) Διαίρεση Μετοχών

GeneOne Life Science, Inc., a biopharmaceutical firm headquartered in Seoul, South Korea, was founded in 1976. The company focuses on the innovation and manufacturing of gene-based biomedical products. Its developmental pipeline features several candidates: GLS-1027 is in Phase I for nephropathy and inflammatory conditions, and also in Phase II trials for COVID-19. Similarly, GLS-1200 is being tested in Phase II for both Rhinosinusitis and COVID-19. Other compounds under development include GLS-3000 and GLS-5310 for SARS-CoV-2, GLS-5100 targeting VZV-Shingles, and GLS-5140 for SFTS. The company is also advancing GLS-5300 in Phase II for MERS, GLS-5700 in Phase I for Zika, and GLS-6150 in Phase I for hepatitis C, alongside GLS-6100 which is in a pre-clinical stage for hepatitis C. Additionally, through its subsidiary VGXI, Inc., GeneOne Life Science offers contract manufacturing services for nucleic acid-based products, specifically DNA plasmids and mRNA, under cGMP standards. The company adopted its current name in April 2014, having previously been known as VGX International Inc.